-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Premenopausal women with idiopathic osteoporosis have marked deficits in bone density, microarchitecture, and strength
Osteoporosis
Recently, a research article was published in the Journal of Clinical Endocrinology & Metabolism, an authoritative journal in the field of endocrine and metabolic diseases.
The researchers conducted an auxiliary analysis of central quantitative computed tomography scans at baseline, after teriparatide treatment, and after denosumab treatment in a randomized trial
Trabecular vBMD (25%), other vBMD parameters and stiffness (21%) were significantly increased after teriparatide treatment (all p<0.
CONCLUSIONS: Continuous treatment with teriparatide and denosumab resulted in a significant increase in bulk density and stiffness, supporting the use of this regimen in premenopausal women with idiopathic osteoporosis
Significant increases in bulk density and stiffness following continuous treatment with teriparatide and denosumab support the use of this regimen in premenopausal women with idiopathic osteoporosis
Original source:
Sanchita Agarwal, et al.
Spine volumetric BMD and strength in premenopausal idiopathic osteoporosis: Effects of teriparatide followed by
denosumab